Expansion Therapeutics

Bringing transformative therapies to patients with severe RNA-mediated diseases.

[Expansion Therapeutics @expansionrx]

Drugging RNA was once considered impossible. Now Big Pharma can't get enough of it - https://t.co/duNaoJtcgP

[Expansion Therapeutics @expansionrx]

Scientists behind RNA-repairing strategy recognized with American Chemical Society’s Nobel Signature award https://t.co/i3nT5nAcBK

[Expansion Therapeutics @expansionrx]

Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases | Business Wire https://t.co/x34Th1wTZ6

[Expansion Therapeutics @expansionrx]

Welcome Renato Skerlj, Ph.D., to the Expansion team! Renato brings more than 25 years of relevant experience advancing small molecule drugs for the treatment of rare diseases.

[Expansion Therapeutics @expansionrx]

Expansion Therapeutics Names Renato Skerlj, Ph.D., Chief Executive Officer and President: https://t.co/JEObj95jtU

[Expansion Therapeutics @expansionrx]

Congratulations to Expansion's Matthew D. Disney on being awarded a prestigious @NINDSnews grant to advance novel, RNA-targeting approaches for hard-to-treat brain diseases including Alzheimer's, Parkinson's, ALS, and others: https://t.co/r5mZjiK0ju @disney_lab @scrippsresearch

[Expansion Therapeutics @expansionrx]

Our initial disease focus is myotonic dystrophy type 1 (DM1), the most frequent cause of adult onset muscular dystrophy. To date, there is no disease-modifying therapy that exists for this rare disease: https://t.co/kMgO91585F #RareDiseaseDay #MyotonicDystrophy

[Expansion Therapeutics @expansionrx]

As many as 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Learn more at: https://t.co/L1slqAYpJr #RareDiseaseDay

[Matt Disney @disney_lab]

Small molecules targeting mRNAs encoding “undruggable” proteins inhibiting their translation is a potential therapeutic strategy - RNA-targeting strategy successfully blocks a vexing driver of Parkinson’s disease | Scripps Research https://t.co/ttdyS7v3o0

[Expansion Therapeutics @expansionrx]

The inaugural "RNA: From Biology to Drug Discovery" symposium was a smashing success, bringing together scientists and innovators developing the next generation of RNA therapeutics @scrippsresearch @disney_lab #RNADay2019

[Scripps Research @scrippsresearch]

Virtually all known drugs work on cell proteins. But Scripps Research’s @disney_lab targets the molecular messengers of our genetic code, opening the door to a plethora of new therapies for hard-to-treat diseases. Learn more and register for RNA Day, Dec 5 https://t.co/yFJ1617QZj

[Expansion Therapeutics @expansionrx]

Join Expansion's Matthew D. Disney and other world-class scientists in the field of RNA therapeutics at the inaugural "RNA: From Biology to Drug Discovery" symposium on December 5, 2019. Learn more or register at https://t.co/QoHZcpdNxO #RNADay2019 @disney_lab

[Expansion Therapeutics @expansionrx]

Expansion Therapeutics Expands Leadership Team with Two Key Appointments; Names World-Renowned Scientist Lynne E. Maquat, Ph.D., to its Scientific Advisory Board: https://t.co/9HXo8MBDJr

[Expansion Therapeutics @expansionrx]

Expansion is a proud sponsor of the inaugural @scrippsresearch Frontiers in Chemical Biology Symposium that includes talks by National Medal of Science winner JoAnne Stubbe, 2018 Nobel Prize Winner @francesarnold, and Expansion's own @RonBreaker and @disney_lab.

[Mia Huang 黃雪兒 @HuangMia]

SoFL and ACS Orlando, join us this coming Friday at Scripps in Jupiter for the 2019 Frontiers in Chemical Biology Symposium! Thank you to our patrons, @IKAworldwide. @thermofisher, @fishersci, @expansionrx. The Symposium is free! https://t.co/aRk50WZ9ZH.

[Expansion Therapeutics @expansionrx]

We seek talented and enthusiastic employees who possess an entrepreneurial and collaborative spirit and embrace our mission of innovation. Learn more about our current career opportunities: https://t.co/U576szxdBa

[Expansion Therapeutics @expansionrx]

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions: https://t.co/QIyqxT3OKJ

[Expansion Therapeutics @expansionrx]

We're honored to be in the good company of other 2019 Xconomy Awards San Diego finalists: https://t.co/nXzmnEskGR @Xconomy

[Expansion Therapeutics @expansionrx]

RNA plays a diverse role in cell biology and is implicated in many diseases, making it an attractive therapeutic target. In a new review, Expansion's Matthew D. Disney discusses the design and development of small molecules interacting with RNA (SMIRNA): https://t.co/CBQNkZJ9oA

[Expansion Therapeutics @expansionrx]

Our understanding of RNA has evolved considerably in recent years, driven by advances in molecular biology and efforts to catalogue all functional elements in the human genome, including elements that act at the protein and RNA levels: https://t.co/g3SOTk5KLm

[Expansion Therapeutics @expansionrx]

With an RNA-binding small molecule that converts HER2-negative breast cancer cells into HER2-positive cells, Expansion's Matthew D. Disney's is pioneering a novel therapeutic approach for triple-negative breast and other hard to treat cancers: https://t.co/yRAKVQ2kHL